Assessing the Quality of Decision Making in the Development and Regulatory Review of Medicines: Identifying Biases and Best Practices

被引:0
|
作者
Magdalena Bujar
Ronan Donelan
Neil McAuslane
Stuart Walker
Sam Salek
机构
[1] Centre for Innovation in Regulatory Science (CIRS),Department of Pharmacy, Pharmacology & Postgraduate Medicine
[2] University of Hertfordshire,undefined
[3] Global Regulatory Affairs,undefined
关键词
quality decision making (QDM); quality decision-making practices (QDMPs); measurement instrument; pharmaceutical company; regulatory agency;
D O I
暂无
中图分类号
学科分类号
摘要
Background: Although the quality of decision making (QDM) in the development and regulatory review of medicines influences the delivery of new products, there appears to be no suitable instrument to assess QDM in this area. The aim of this study was to assess differences in QDM using a validated instrument, the Quality of Decision-Making Orientation Scheme (QoDoS), to identify best practices and biases affecting individuals and their organization, as well as to assess differences in decision-making behaviors between pharmaceutical companies and regulatory agencies. QoDoS also enables the measurement against 10 quality decision-making practices (QDMPs) that underpin a quality process. Methods: QoDoS, consisting of 47 items that assess individual and organizational decision-making approaches and influences, was completed by 76 participants from regulatory agencies and pharmaceutical companies. Results: Having a systematic, structured approach to aid in decision making is achieved to a greater extent at an individual level (72%) compared with that of the organization (38%). Key differences between company and agency decision making were uncovered. While it was recognized that both stakeholders felt that their decision making could be improved (100% agencies; 92% companies), training in the science of decision making was rarely provided. Conclusions: QoDoS has the ability to measure differences in QDM between individuals and organizations within companies and agencies. The benefits of assessing QDMPs with QoDoS include enabling an increased awareness of biases and best practices that should be incorporated into a decision-making framework; increasing productivity and reducing uncertainty around decision making, thereby resulting in more predictable outcomes for organizations. In addition, it provides a basis for discussion of the issues in decision making within an organization as well as between stakeholders to encourage a level of partnership. Finally, measurements of QDM will enable trust, consistency, transparency, and timeliness to be built into critical decisions that affect medicines’ availability.
引用
收藏
页码:250 / 256
页数:6
相关论文
共 50 条
  • [1] Assessing the Quality of Decision Making in the Development and Regulatory Review of Medicines: Identifying Biases and Best Practices
    Bujar, Magdalena
    Donelan, Ronan
    McAuslane, Neil
    Walker, Stuart
    Salek, Sam
    [J]. THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2017, 51 (02) : 250 - 256
  • [2] A Process for Evaluating Quality Decision-Making Practices During the Development, Review and Reimbursement of Medicines
    Bujar, Magdalena
    McAuslane, Neil
    Walker, Stuart
    Salek, Sam
    [J]. INTERNATIONAL JOURNAL OF HEALTH POLICY AND MANAGEMENT, 2022, 11 (02) : 128 - 137
  • [3] Evaluating Quality of Decision-Making Processes in Medicines' Development, Regulatory Review, and Health Technology Assessment: A Systematic Review of the Literature
    Bujar, Magdalena
    McAuslane, Neil
    Walker, Stuart R.
    Salek, Sam
    [J]. FRONTIERS IN PHARMACOLOGY, 2017, 8
  • [4] Towards establishing criteria and best practices for analysing omic data for regulatory decision making
    Tong, Weida
    [J]. TOXICOLOGY LETTERS, 2017, 280 : S15 - S15
  • [5] Quality of Regulatory Decision-Making Practices: Issues Facing Companies and Agencies
    Magdalena Bujar
    Neil McAuslane
    Sam Salek
    Stuart Walker
    [J]. Therapeutic Innovation & Regulatory Science, 2016, 50 : 487 - 495
  • [6] Quality of Regulatory Decision-Making Practices: Issues Facing Companies and Agencies
    Bujar, Magdalena
    McAuslane, Neil
    Salek, Sam
    Walker, Stuart
    [J]. THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2016, 50 (04) : 487 - 495
  • [7] Development of best practices in physiologically based pharmacokinetic modeling to support clinical pharmacology regulatory decision-making-A workshop summary
    Jean, Daphney
    Naik, Kunal
    Milligan, Lauren
    Hall, Stephen
    Mei Huang, Shiew
    Isoherranen, Nina
    Kuemmel, Colleen
    Seo, Paul
    Tegenge, Million A.
    Wang, Yaning
    Yang, Yuching
    Zhang, Xinyuan
    Zhao, Liang
    Zhao, Ping
    Benjamin, Jessica
    Bergman, Kimberly
    Grillo, Joseph
    Madabushi, Rajanikanth
    Wu, Fang
    Zhu, Hao
    Zineh, Issam
    [J]. CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2021, 10 (11): : 1271 - 1275
  • [8] Regulatory Review: How Do Agencies Ensure the Quality of Decision Making?
    Liberti, L.
    McAuslane, N.
    Patel, P.
    Breckenridge, A.
    Eichler, H. G.
    Peterson, R.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 94 (03) : 305 - 308
  • [9] Best Evidence to Support Regulatory Decision-Making
    Blake, K.
    Fitt, H.
    Hidalgo-Simon, A.
    Arlett, P.
    [J]. DRUG SAFETY, 2013, 36 (09) : 866 - 866
  • [10] Rationality in medical decision making: a review of the literature on doctors' decision-making biases
    Bornstein, BH
    Emler, AC
    [J]. JOURNAL OF EVALUATION IN CLINICAL PRACTICE, 2001, 7 (02) : 97 - 107